Expanding the Role of Neuromodulation for Overactive Bladder: New Indications and Alternatives to Delivery

Current Bladder Dysfunction Reports

Volumn 6, Issue 1, 2011, Pages 25-30

  Le, Ngoc Bich ^a   Kim, Ja Hong ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiac pacemaker; Cost effectiveness; Efficacy; InterStim; Neurogenic bladder; Neurostimulation; Overactive bladder; Peripheral nerve stimulation; Posterior tibial nerve stimulation; Pudendal nerve stimulation; Sacral nerve stimulation; Sacral neuromodulation; Safety; Urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; TOLTERODINE;

BLADDER RECONSTRUCTION; COST EFFECTIVENESS ANALYSIS; HEMATOMA; HUMAN; IMPLANTATION; INFECTION; LOWER URINARY TRACT SYMPTOM; MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE; NEUROMODULATION; OVERACTIVE BLADDER; PAIN; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SACRAL NERVE STIMULATION; SCORING SYSTEM; SINUS NODE; THERAPY EFFECT; URINE INCONTINENCE;

EID: 84864796189     PISSN: 19317212     EISSN: 19317220     Source Type: Journal    
DOI: 10.1007/s11884-010-0074-3     Document Type: Review

References (21)

1. Abrams P, Cardozo L, Fall M, et al.: The standardization of terminology of lower urinary tract function: Report from Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-178.
2. Kelleher CJ, Cardozo LD, Khullar V, et al.: A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder. British Journal of Obstetrics and Gynaecology 1997, 104: 988-993.
3. Spinelli M, Sievert KD.: Latest technologic and surgical developments in using InterStim therapy for sacral neuromodulation: Impact on treatment success and safety. Eur Urol 2008, 54: 1287-96.
4. Leng WW, Chancellor MB: How sacral nerve stimulation neuromodulation works. Urol Clin North Am 2005; 32: 11-8.
5. • Siddiqui NY, Wu JM, Amundsen CL: Efficacy and adverse events of sacral nerve stimulation for overactive bladder: A systematic review. Neurourol Urodyn 2010, 29: S18-S23. This is a timely review of the available literature on SNS that contributes to the evidence-based approach to treating refractory OAB.
6. Amundsen CL, Romero AA, Jamison MG, et al.: Sacral neuromodulation for intractable urge incontinence: Are there factors associated with cure? Urology 2005; 66: 746-50.
7. •• Siddiqui NY, Amundsen CL, Visco AG, et al.: Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol 2009; 182: 2799-804. Cost-effectiveness, especially in terms of medical treatment, is an integral issue in the contemporary discussions on health care reform and the economy.
8. Roth TM: Sacral neuromodulation and cardiac pacemakers. Int Urogynecol J 2010; 21: 1035-1037.
9. Ridout AE, Yoong W: Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy. Int Urogynecol J Pelvic Floor Dysfunct 2010; 21: 1035.
10. • Peters KM, MacDiarmid SA, Wooldridge LS et al.: Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009; 178: 2029. This is a laudable effort to generate level I evidence in this field.
11. • Peters KM, Carrico DJ, Perez-Marrero RA, et al.: Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010, 183: 1438-43. This is another laudable effort to generate level I evidence in this field.
12. Yoong W, Ridout AE, Damodaram M, et al.: Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability: outcomes following a shortened 6-week protocol. BJU Int 2010 Jun 29 (Epub ahead of print).
13. • MacDiarmid SA, Peters KM, Shobeiri SA, et al.: Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol 2010; 183: 234. This article addresses a key concern surrounding the use of PTNS in the treatment of OAB.
14. van der Pal F, van Balken MR, Heesakkers JP, et al.: Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: Is maintenance treatment necessary? British Journal of Urology International 2006, 97: 547-560.
15. Peters KM, Killinger KA, Boguslawski BM, et al.: Chronic pudendal neurostimulation: Expanding available treatment options for refractory urologic symptoms. Neurourol Urodyn 2001, 29: 1267-1271.
16. Sievert KD, Matzel K, Ratto C, et al.: Permanente sakrale Neuromodulation mittels InterStim: Ergebnisse einer Anwenderbefragung zu aktuellen technischen Entwicklungen. J Urol Urogynakol 2007, 14: 14-6.
17. Capitanucci ML, Camanni D, Demelas F, et al.: Long-term efficacy of percutaneous tibial nerve stimulation for different types of lower urinary tract dysfunction in children. J Urol 2009, 182: 2056.
18. • van Rey FS, Heesakkers JP: Applications of neurostimulation for urinary storage and voiding dysfunction in neurological patients. Urol Int 2009; 81: 373. This article raises the possibility of using neuromodulation to treat voiding dysfunction in patients with neurological disorders.
19. Scheepens WA, Jongen MM, Nieman FH, et al.: Predictive factors for sacral neuromodulation in chronic lower tract dysfunction. Urology 2002, 60: 598-602.
20. Finazzi AE, Parisi A, Petta F, et al.: Percutaneous tibial nerve stimulation in the treatment of lower urinary tract dysfunction secondary to multiple sclerosis. Paper presented at the meeting of the International Continence Society. Florence, Italy; 2003.
21. Rasmussen NT, Guralnick ML, O'Connor RC: Successful use of sacral neuromodulation after failed bladder augmentation. Can Urol Assoc J 2009, 3: E49-E50.